Altimmune, Inc. — Director's Dealing 2021

Dec 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2021-12-14

Reporting Person: Drutz David (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-14	Common Stock, par value $0.0001	M	139	$2.4	Acquired	17812	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-14	Stock Options (option to buy)	$2.4	M	139	Disposed	2022-01-03	Common Stock, par value $0.0001 (139)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001	333	Indirect

Footnotes

F1: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.

F2: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018.

F3: This option is fully vested and exercisable as of the date hereof.